Eloxx Pharmaceuticals reported Q3 2026 financial results and provided a business update on its rare kidney disease pipeline, including the dosing of the first two patients in the Phase 2b EXACT study for Alport syndrome. The company also received FDA IND clearance for its Phase 2 EXPRESS study in ADPKD and ended the quarter with $56.3 million in cash.
Term
Q3 2026
“The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease.”
Sumit Aggarwal, President and Chief Executive Officer
Eloxx Pharmaceuticals is a clinical-stage biotechnology company focused on developing exaluren for Alport Syndrome and ADPKD. The company reports significant operating losses and indicates a substantial need for additional funding to continue as a going concern and maintain its Nasdaq listing.
Eloxx Pharmaceuticals has expanded its Board of Directors from five to six members and appointed Geno J. Germano as an independent director. Mr. Germano is a 35-year pharmaceutical industry veteran who previously served as CEO of Elucida Oncology and Group President at Pfizer. He will serve a term expiring at the company's 2027 annual meeting of stockholders.